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Familial clustering of malignancies provides a unique opportunity to identify molecular causes of
cancer. Polycythemia vera (PV) is a myeloproliferative disorder due to an unknown somatic stem
cell defect that leads to clonal myeloid hyperproliferation. We studied six families with PV. The
familial predisposition to PV appears to follow an autosomal dominant inheritance pattern with
incomplete penetrance. All examined females informative for a transcriptional clonality assay
had clonal hematopoiesis. We excluded linkage between PV and a number of previously
proposed candidate disease loci (c-mpl, EPOR, 20q, 13q, 5q, 9p). Therefore, mutations at these
loci are unlikely primary causes of familial PV. The finding of erythropoietin-independent
erythroid progenitors in normal family members indicated the presence of the PV stem cell clone
in  their  hematopoiesis.  This  finding,  together  with  clonal  hematopoiesis  in  the  affected
individuals,  supports  the  hypothesis  of  multiple  genetic  defects  involved  in  the  early
pathogenesis of PV.
jprchal@bcm.tmc.edu
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Sporadic myeloproliferative disorders (MPD) are due to an acquired mutation of a single
hematopoietic  cell  resulting  in  clonal  circulating  myeloid  progeny.
1  Accumulation  of
erythrocytes is a hallmark of polycythemia vera (PV) while the accumulation of platelets,
neutrophils, basophils, and eosinophils is variable. The molecular lesion responsible for PV is
unknown. The erythroid progenitors in PV form erythropoietin-independent erythroid colonies
(EEC) in clonogenic cultures in the absence of exogenous erythropoietin (Epo).
2 This unique
feature permits the distinction of PV from other primary polycythemias with or without a family
history.
3,4 The EEC assay also identifies an early PV stage that lacks the full PV phenotype and
allows differentiation of PV in those patients initially presenting with thrombocytosis from those
individuals having essential thrombocythemia.
5 Familial clustering of polycythemia is seen in
congenital polycythemic states including primary familial and congenital polycythemia, Chuvash
polycythemia, high oxygen affinity globin mutants, and BPG mutase deficiency.
6 However, few
case reports of familial occurrence of PV have been reported.
7-10
Patients, Materials and Methods
All affected family members had classical diagnosis of PV based on the PV Study Group
criteria.
11 All studies were performed under approved Institutional Review Board protocols
(Baylor College of Medicine and Univ. Alabama at Birmingham) and all subjects included in
this study provided written consent to perform DNA and cell culture studies on their blood
samples.
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linkage analysis are listed elsewhere.
12,13 Microsatellite PCR for the EPOR and c-mpl genes were
done as previously described.
14,15
Results and discussion
We studied six Caucasian families of heterogeneous ethnic background, each with multiple
members with PV (Figure 1a). We detected EEC in peripheral blood cultures in all the affected
family members in all families. The clinical findings are summarized in Table 1; these results of
clinical findings represent all of the available patients and these were not pre-selected. In
addition to the affected members with the full PV phenotype, we tested family members without
PV for the presence of EEC in their peripheral blood. We identified subjects in families A and B
who had no clinical signs or symptoms of PV but EEC were present in their peripheral blood
(subjects A-4, A-6, A-9, A-14, A17, B-1). Clonality was demonstrated in the informative
females with full PV phenotype (Table 1, Figure 1b). The members with partial phenotype (EEC
only)  were  polyclonal  indicating  the  contribution  of  normal  stem  cells  to  productive
hematopoiesis, and therefore, lack of clinical symptoms of PV. To examine whether the presence
of EEC is due to a somatic mutation or an inherited mutant gene, we isolated the Epo-
independent erythroid cell population and analyzed its clonality (this sample consisted of
approximately 500-1000 BFUE's harvested from 10 methylcellulose plates followed by MACS
sorting for glycophorin A.  Each BFUE consists of approximately 800-2000 proerythroblasts).
We detected clonal EEC in one informative female who had otherwise polyclonal hematopoiesis;
please note that the T-cells X-chromosome allelic usage appears skewed; however, the observed
skewing is within the range which we reported in normal hematopoietic progeny  (Figure 1b). 
16
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decreased penetrance. If the finding of EEC is considered as an early sign of the PV phenotype,
the penetrance increases. Four out of the six families (A-D) were used for linkage analysis since
these consisted of at least two affected siblings. It is possible that the clustering of PV in family
E and F could be by chance only and that we could have a selection bias to recruit these families
since families of unusual polycythemic disorders have been referred to us for over a decade. For
these pedigrees, we calculated the power to detect linkage using the SIMLINK software
17 which
predicted a maximum LOD score of 4.4 for the given pedigree structures. The simulated LOD
scores further increased to 5.2 when the subjects positive for EEC were considered as affected
(data not shown). Using these families, we could examine a number of candidate loci that were
previously proposed to play a role in MPD, or PV in particular. We analyzed the linkage between
the PV phenotype and the commonly deleted regions on chromosomes 20q, 13q, 5q that were
found as genetic aberrations in PV.
18,19 In addition, the thrombopoietin receptor (c-mpl) and Epo
receptor (EPOR) genes have been proposed in the pathogenesis of myeloproliferative disorders
including PV.
20,21 Recently, we reported the presence of loss of heterozygosity (LOH) involving
chromosome 9p as the most common clonal defect in sporadic PV.
12 We detected LOH on
chromosome 9p in subjects A01 and B02 (Table 1). We performed linkage analysis using
microsatellite markers mapping to these loci. Only the affected subjects with the full PV
phenotype were considered “affected” in the linkage analysis. Since LOD scores below –2.0 are
considered exclusion of linkage, we could exclude linkage between the PV phenotype and all the
tested loci. LOD scores for the EPOR and c-mpl genes were –3.16 and –2.24, respectively. The
commonly deleted regions found in sporadic MPD were also convincingly excluded with LOD
scores –4.40 for 20q, –4.79 for 13q, and –6.27 for 5q. We also fully excluded chromosome 9p
region of LOH. These results suggest that the frequently observed somatic mutations in MPD
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do not target the primary PV locus.
The clinical analysis of the affected family members confirmed that they are phenotypically
identical to sporadic PV. Familial occurrence of PV provides a unique insight in to the stages of
PV since we could identify affected members in an early stage of the disease using the EEC assay.
This is not possible in sporadic PV since individuals are only identified when symptomatic.
Thrombocythemia  was  shown  to  be  the  first  abnormality  seen  in  some  PV  subjects
5  and
interestingly in families C and D, thrombocythemia occurred prior to elevation of hematocrit. In
all the affected informative females, we observed clonal circulating myeloid cells as seen in
sporadic PV; in some clonality could not be determined because a) patients were genotyped for
exonic polymorphisms of active X-chromosome genes used for the clonality assays and were not
informative, b) failure to get informed consent for this follow-up study, or c) patients were no
longer available or willing to participate in our study.
4 Clonal hematopoiesis is a marker of fully
developed PV. In families A and B, we observed hematologically normal subjects with EEC
present in their peripheral blood. In one of these cases we proved the clonal origin of the Epo-
independent cells but the rest of the myeloid cells were polyclonal. Thus it is possible that in pre-
symptomatic PV, within polyclonal hematopoiesis the PV stem cell clone may be present but its
contribution to blood production is limited. At this stage, the progeny of the PV clone can be
detectable by the EEC assay. In the symptomatic stage, the PV clone loses regulation and expands
and clonal hematopoiesis appears. It remains to be established if in the individuals with PV who
present with thrombocytosis prior to elevation of hematocrit, thrombocytosis precedes (such as
seen in subject C02 and in one female with sporadic PV we studied previously) or follows
establishment of clonal circulating hematopoietic progeny.
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etiology of familial PV. The presence of both inherited and acquired mutations in familial PV
allows several interpretations of the disease etiology. As seen in other familial predispositions to
cancer (such as retinoblastoma), a mutant non-functional copy of the gene is inherited in the
families followed by an acquired mutation of the remaining wild type allele. The disease initiates
after both alleles of the gene are mutated (mutation of one allele being inherited and the mutation
of the second allele being acquired). Thus in families with PV predisposition, PV phenotype will
be expected to develop at the earlier age than that seen in sporadic PV. This has indeed been a
case in families B, E, and F. It is possible that the stem cell clone established in this initial stage
undergoes further mutagenesis resulting in acceleration of clonal expansion. An alternative
interpretation assumes mutations in two or more genes, mutation of one gene being inherited and
mutation(s) of other gene(s) being acquired. However, if more than one gene can contribute to
the development of a final PV phenotype this will make PV a genetically heterogeneous disorder
and some of the positional cloning data interpretation would not be valid. Loss of gene function
is a necessary component of the first model, whereas in the second model, gain of function
mutations may also be present together with loss of function mutations. In both models, the
acquired mutations are responsible for the presence of clonal hematopoiesis. The presence of
incomplete penetrance, observed in the families, is compatible with both models.
The chromosomal localization of the “primary PV mutation” remains unknown. The PV
phenotype did not show linkage to any of the loci implicated in PV to date. Families with
multiple members with PV should prove fundamental in identification of the PV predisposition
gene as they offer the possibility for genome-wide linkage analysis and positional cloning.
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Figure 1
A. Pedigrees of six families with polycythemia vera (PV). Affected individuals are indicated
with black. In families A and B, black points indicate hematologically normal family members
with Epo-independent erythroid cell detectable in their peripheral blood cultures. B. Clonality
analysis of individuals A01 and A06 using the IDS gene exonic polymorphism. RNA isolated
from T lymphocytes (T), granulocytes (GRA), platelets (PLT), and Epo-independent erythroid
cells (EEC) were used for the analysis. The presence of only one expressed allele of the IDS
gene in platelets, granulocytes, and Epo-independent erythroid cells is consistent with clonal
origin of cells. C. Exclusion of linkage between chromosome 9p microsatellite markers and PV.
LOD scores below –2.0 satisfy the criteria of exclusion of linkage.
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! ! ! Age at Hct Hgb PLT Spleno- ! Clonality EEC
Subject Diagnosis Sex diagnosis (%) (g/dl) (K/ml) megaly Karyotype assay
A01 PV F 58 55 18 443 + 9pLOH CL present
A03 PV F 62 64 19.7 190 + normal CL present
A04 normal F - 42.2 14.7 310 - nd nd present
A06 normal F - 46.7 16.2 204 - nd PO, EEC-CL present
B02 PV F 31 45.7 12.7 438 - 9pLOH CL present
B04 PV M 33 48.4 16.2 284 - normal nd present
C01 PV F 80 54.2 17.7 710 nd nd nd nd
C02 PV F 72 40.9 13.6 2,430 - nd CL present
C03 PV F 66 35.9 12 1,995 + normal nd present
D03 PV F 29 46 16.2 1,190 - nd nd nd
D06 PV M 48 55 19.5 910 - normal nd nd
E03 PV M 25 57.3 19.7 729 + normal nd present
E04 PV M 5 61 19.6 614 + nd nd present
F01 PV M 52 56.6 18.2 65 - nd nd present
F02 PV F 30 50 16.4 168 - normal CL present
(CL – clonal, PO – polyclonal, EEC – Epo-independent colonies, nd – not determined)
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